<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509612</url>
  </required_header>
  <id_info>
    <org_study_id>5</org_study_id>
    <nct_id>NCT01509612</nct_id>
  </id_info>
  <brief_title>Additive Homeopathy in Cancer Patients</brief_title>
  <acronym>HIC</acronym>
  <official_title>Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Lung Tumors With or Without &quot;add-on&quot; Homeopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the validity of their previous results in a randomized&#xD;
      prospective, placebo-controlled, double-blind, multicenter controlled evaluation of&#xD;
      questionnaires in patients with advanced malignant tumors. The investigators plan to compare&#xD;
      the treatment outcome (quality of life and survival) in tumor patients, receiving standard or&#xD;
      &quot;add-on&quot; homeopathic treatment.&#xD;
&#xD;
      The null hypothesis is that &quot;add-on&quot; homeopathic treatment does not create a benefit for&#xD;
      cancer patients. In addition the investigators evaluate survival time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EORTC-QLQ-C30, SF-36 as well as a VAS scale for subjective well-being will be filled out&#xD;
      by the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EORTC-QLQ-C30 Score</measure>
    <time_frame>baseline and at 18 weeks</time_frame>
    <description>Quality of life was evaluated by using the Global Health Status assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30), which was completed by participants throughout the study.&#xD;
The score of the scale ranges from 0-100, where high values mean good health status, while lower values indicate poor health status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years for the individual patient (=whole study duration)</time_frame>
    <description>Survival was assessed by chart review, at every study visit (every 9 weeks throughout the trial), and by information of the central mortality registry of Austria</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>Additive homeopathy in cancer patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Additive homeopathic placebo globules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Additive classical homeopathy</intervention_name>
    <description>Homeopathic remedies every 2 to 3 months</description>
    <arm_group_label>Additive homeopathy in cancer patients</arm_group_label>
    <other_name>Classical homeopathic remedies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Homeopathic Placebo globules</intervention_name>
    <description>Homeopathic placebo globules every 2 to 3 months</description>
    <arm_group_label>Additive homeopathic placebo globules</arm_group_label>
    <other_name>Homeopathic Placebo globules looking identical to verum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Clinical diagnosis of advanced tumor stages of non small-cell lung carcinoma (NSCLC)&#xD;
             IIIB, IIIC, IV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  sensitizing mutation of the EGFR gene or translocation of the ALK gene&#xD;
&#xD;
          -  refusal to sign informed consent&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  hematological, hepatic, or renal pathology&#xD;
&#xD;
          -  coronary heart disease&#xD;
&#xD;
          -  history of secondary tumor&#xD;
&#xD;
          -  major surgery within 4 weeks prior to study entry&#xD;
&#xD;
          -  active infection and symptomatic peripheral neuropathy&#xD;
&#xD;
          -  central nervous system metastases unless the metastases were treated and stable&#xD;
&#xD;
          -  active autoimmune disease&#xD;
&#xD;
          -  use of systemic immunosuppressive treatment&#xD;
&#xD;
          -  use of systemic treatment during the previous 2 years&#xD;
&#xD;
          -  active interstitial lung disease, or a history of pneumonitis for which&#xD;
             glucocorticoids were prescribed&#xD;
&#xD;
          -  previous systemic therapy for metastatic disease or previous irradiation&#xD;
&#xD;
          -  use of any complementary and/or alternative therapy, including homeopathy other than&#xD;
             the research treatment during the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Frass, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael Frass</name>
      <address>
        <city>Wien</city>
        <zip>1120</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.homeopathicresearch.org</url>
    <description>Related info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 7, 2012</study_first_submitted>
  <study_first_submitted_qc>January 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <results_first_submitted>February 23, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 3, 2020</results_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Michael Frass</investigator_full_name>
    <investigator_title>Principal Investigator, Prof. Dr., Director, Outpatient Unit Homeopathy in tumor patients</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>additive homeopathy</keyword>
  <keyword>patients with advanced malignant tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT01509612/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from February 2012 to July 2017</recruitment_details>
      <pre_assignment_details>Screened participants were excluded from participation in the study when mutations had been observed, these were treated as screening failures and not included in the trial (= not randomized, n=8).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Homeopathic Placebo Globules</title>
          <description>Cancer patients received homeopathic placebo remedies</description>
        </group>
        <group group_id="P2">
          <title>Additive Classical Homeopathy in Cancer Patients</title>
          <description>Lung cancer patients receive additive classical homeopathy with homeopathic remedies</description>
        </group>
        <group group_id="P3">
          <title>No Intervention Group</title>
          <description>The patients in this group received no intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Additive Homeopathy in Cancer Patients</title>
          <description>Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules&#xD;
Additive classical homeopathy: Homeopathic remedies every 2 to 3 months</description>
        </group>
        <group group_id="B2">
          <title>Additive Homeopathic Placebo Globules</title>
          <description>Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules&#xD;
Homeopathic Placebo globules: Homeopathic placebo globules every 2 to 3 months</description>
        </group>
        <group group_id="B3">
          <title>No Intervention</title>
          <description>Lung cancer patients receiving conventional chemo- and/or radiation therapy but neither homeopathic remedies nor homeopathic placebo globules, these patients served as a non-intervention control group</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="8.8"/>
                    <measurement group_id="B2" value="62.5" spread="8.9"/>
                    <measurement group_id="B3" value="63.9" spread="9.1"/>
                    <measurement group_id="B4" value="63.2" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EORTC-QLQ-C30</title>
          <description>At baseline the quality of life questionnaire (EORTC-QLQ-C30) was completed by all participating subjects receiving placebo or homeopathy</description>
          <population>The quality of life assessment was done in the two intervention groups (homeopathy or placebo), but was not done in control patients who received no intervention.&#xD;
Therefore, no data are presented for the &quot;No Intervention&quot; group.</population>
          <units>units on a scale from 1 to 4</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="25.8"/>
                    <measurement group_id="B2" value="51.2" spread="28.0"/>
                    <measurement group_id="B4" value="48.8" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>EORTC-QLQ-C30 Score</title>
        <description>Quality of life was evaluated by using the Global Health Status assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30), which was completed by participants throughout the study.&#xD;
The score of the scale ranges from 0-100, where high values mean good health status, while lower values indicate poor health status.</description>
        <time_frame>baseline and at 18 weeks</time_frame>
        <population>Data not collected for the no Intervention Group</population>
        <group_list>
          <group group_id="O1">
            <title>Homeopathic Placebo Globules</title>
            <description>Cancer patients received homeopathic placebo remedies</description>
          </group>
          <group group_id="O2">
            <title>Additive Classical Homeopathy in Cancer Patients</title>
            <description>Lung cancer patients receive additive classical homeopathy with homeopathic remedies</description>
          </group>
          <group group_id="O3">
            <title>No Intervention Group</title>
            <description>Lung cancer patients received conventional anti-cancer therapy, but neither homeopathic remedies nor homeopathic placebo globules. Data not collected for the no Intervention Group.</description>
          </group>
        </group_list>
        <measure>
          <title>EORTC-QLQ-C30 Score</title>
          <description>Quality of life was evaluated by using the Global Health Status assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30), which was completed by participants throughout the study.&#xD;
The score of the scale ranges from 0-100, where high values mean good health status, while lower values indicate poor health status.</description>
          <population>Data not collected for the no Intervention Group</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="28.0"/>
                    <measurement group_id="O2" value="46.6" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.397</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Survival was assessed by chart review, at every study visit (every 9 weeks throughout the trial), and by information of the central mortality registry of Austria</description>
        <time_frame>2 years for the individual patient (=whole study duration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Additive Homeopathy in Cancer Patients</title>
            <description>Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules&#xD;
Additive classical homeopathy: Homeopathic remedies every 2 to 3 months</description>
          </group>
          <group group_id="O2">
            <title>Additive Homeopathic Placebo Globules</title>
            <description>Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules&#xD;
Homeopathic Placebo globules: Homeopathic placebo globules every 2 to 3 months</description>
          </group>
          <group group_id="O3">
            <title>No Intervention</title>
            <description>No homeopathic or placebo intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Survival was assessed by chart review, at every study visit (every 9 weeks throughout the trial), and by information of the central mortality registry of Austria</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only those groups were compared who received an intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study for each participant lasted 24 months</time_frame>
      <desc>The adverse events reporting in this study differed from the definition of clinicaltrials.gov.&#xD;
Treatment-related (serious) and non-treatment-related adverse events have been reported.&#xD;
No severe treatment-related (serious) or non-treatment-related adverse event has been identified attributed to the study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Homeopathic Placebo Globules</title>
          <description>Cancer patients received homeopathic placebo remedies.&#xD;
Treatment emergent and serious adverse events were documented.</description>
        </group>
        <group group_id="E2">
          <title>Additive Classical Homeopathy in Cancer Patients</title>
          <description>Lung cancer patients receive additive classical homeopathy with homeopathic remedies&#xD;
Treatment emergent and serious adverse events were documented.</description>
        </group>
        <group group_id="E3">
          <title>No Intervention Group</title>
          <description>Patients received no intervention.&#xD;
Treatment emergent and serious adverse events were documented.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Frass, MD</name_or_title>
      <organization>Medical University of Vienna</organization>
      <phone>+436645453040</phone>
      <email>office@ordination-frass.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

